Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2011 Jul 1.

Published in final edited form as: Semin Hematol. 2010 Jul;47(3):289–298. doi: 10.1053/j.seminhematol.2010.03.002

Table 3.

Common non-bleeding adverse events in trials of romiplostim and eltrombopag.

Adverse event	Romiplostim trials^a		Eltrombopag trials^b
Adverse event	Drug (16,062 patient-weeks)	Placebo (1,032 patient-weeks)	Drug (9,788 patient-weeks)	Placebo (450 patient-weeks)
Nasopharyngitis/URI	1.1 (173)	1.2 (12)	1.1 (112)	0.7 (3)
Headache	0.8 (126)	1.3 (13)	0.8 (78)	2.4 (11)
Fatigue	0.7 (102)	1.2 (12)	0.5 (45)	1.1 (5)
Arthralgia	0.5 (88)	0.9 (9)	0.4 (38)	0.9 (4)
Diarrhea	0.5 (83)	0.7 (7)	0.4 (38)	0.7 (3)

Events per 100-patient weeks are shown with number of events in parentheses. URI, upper respiratory infection.

^a

Includes a pooled analysis of the 6-week phase II and 24-week phase III trials and the extension study of romiplostim.

^b

Includes a pooled analysis of the 6-week phase II trials, the 6-week phase III trial, and the extension study of eltrombopag.